Study design of the Routine Outcome Monitoring for Geriatric Psychiatry & Science (ROM-GPS) project; a cohort study of older patients with affective disorders referred for specialised geriatric mental health care. by Oude Voshaar, R.C. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/207225
 
 
 
Please be advised that this information was generated on 2019-12-31 and may be subject to
change.
STUDY PROTOCOL Open Access
Study design of the Routine Outcome
Monitoring for Geriatric Psychiatry &
Science (ROM-GPS) project; a cohort study
of older patients with affective disorders
referred for specialised geriatric mental
health care
Richard C. Oude Voshaar1* , Ton D. F. Dhondt2, Mario Fluiter2, Paul Naarding3, Sanne Wassink3,
Maureen M. J. Smeets4, Loeki P. R. M. Pelzers4, Astrid Lugtenburg5, Martine Veenstra1,5, Radboud M. Marijnissen6,
Gert-Jan Hendriks6, Lia A. Verlinde7, Robert A. Schoevers1 and Rob H. S. van den Brink1
Abstract
Background: Affective disorders, encompassing depressive-, anxiety-, and somatic symptom disorders, are the most
prevalent mental disorders in later life. Treatment protocols and guidelines largely rely on evidence from RCTs
conducted in younger age samples and ignore comorbidity between these disorders. Moreover, studies in geriatric
psychiatry are often limited to the “younger old” and rarely include the most frail. Therefore, the effectiveness of
treatment in routine clinical care for older patients and impact of ageing characteristics is largely unknown.
Objective: The primary aim of the Routine Outcome Monitoring for Geriatric Psychiatry & Science (ROM-GPS) –
project is to examine the impact of ageing characteristics on the effectiveness of treatment for affective disorders in
specialised geriatric mental health care.
Methods: ROM-GPS is a two-stage, multicentre project. In stage one, all patients aged ≥60 years referred to
participating outpatient clinics for specialised geriatric mental health care will be routinely screened with a semi-
structured psychiatric interview, the Mini International Neuropsychiatric Interview and self-report symptom severity
scales assessing depression, generalized anxiety, hypochondria, and alcohol use. Patients with a unipolar depressive,
anxiety or somatic symptom disorder will be asked informed consent to participate in a second (research) stage to be
extensively phenotyped at baseline and closely monitored during their first year of treatment with remission at one-
year follow-up as the primary outcome parameter. In addition to a large test battery of potential confounders, specific
attention is paid to cognitive functioning (including computerized tests with the Cogstate test battery as well as paper
and pencil tests) and physical functioning (including multimorbidity, polypharmacy, and different frailty indicators). The
study is designed as an ongoing project, enabling minor adaptations once a year (change of instruments).
(Continued on next page)
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Discussion: Although effectiveness studies using observational data can easily be biased, potential selection bias can
be quantified and potentially corrected (e.g. by propensity scoring). Knowledge of age-related determinants of
treatment effectiveness, may stimulate the development of new interventions. Moreover, studying late-life depressive,
anxiety and somatic symptom disorders jointly enables data-driven studies for more optimal classification of these
disorders in later life.
Trial registration: Dutch Trial Register: NL6704 (www.trialregister.nl). Retrospectively registered on 2017-12-05.
Keywords: Affective disorder, Depressive disorder, Anxiety disorder, Somatic symptom disorder, Aged, Aged, 80 years
and over, Cohort, Treatment outcome, Routine outcome monitoring
Background
Affective disorders, encompassing depressive, anxiety,
and somatic-symptom disorders, are the most prevalent
mental health disorders in later life. Reported prevalence
rates centre around 10% for each of these groups of
disorders, although studies vary due to differences in the
age cut-off, time window, level of caseness, and diagnos-
tic instrument applied [1–5]. The disease burden of
affective disorders is high, as each of these disorders is
associated with a lower quality of life, poorer prognosis
of comorbid somatic diseases, and increased health care
use [5–7]. Moreover, comorbidity between affective
disorders is the rule rather than the exception, with up
to 75% of the patients suffering from disorders out of at
least two of the three diagnostic groups [8]. Comorbidity
increases the disease burden more than can be explained
by the sum of the individual disorders [9]. Despite these
facts, comorbidity between affective disorders is largely
neglected in disorder specific treatment guidelines as
well as disorder specific care paths that have been imple-
mented in mental health organisations.
Nowadays, the provision of mental health care averts
15% of the disease burden (measured as ‘years lived with
disability’) caused by depressive disorders and 13% of
the disease burden caused by anxiety disorders by 13%
[10]. Over 50% of depressed patients across all age
groups will not achieve remission with their first treat-
ment [11]. Ultimately, 20–30% of depressed patients will
not achieve full recovery despite access to multiple
interventions [12]. Although affective disorders can be
effectively treated in later life, data show that results
with respect to depression as well as anxiety disorders
worsen with increasing age [13–15]. Recovery may well
be slower [16] and in case of remission, relapses more
frequently occur compared to younger-aged patients
[17]. Several explanations can be put forward why the
effectiveness of treatment decreases with increasing age.
Firstly, most treatment protocols have been developed in
younger adults, ignoring specific age-related somatic
comorbidities like somatic multimorbidity, physical
frailty, and mild cognitive impairment, as well as age-
related psychosocial adversities, like loss of a spouse or
loneliness. Secondly, empirical data on the treatment of
older persons with affective disorders, especially studies
addressing specific characteristics of older persons, is
hardly available. To our knowledge, no randomised con-
trolled treatment trials have been conducted for
somatization in later life [18] and only a few for late-life
anxiety [19]. Most studies in late-life affective disorders
have addressed the treatment of depression. Unfortu-
nately, treatment response and remission are less likely
in older compared to younger patients [20], and efficacy
even decreases with age in samples of 60 years and older
[13]. Findings that treatment efficacy of affective disor-
ders decreases with the patients’ age, suggest that age-
related characteristics may be involved. A systematic
review, however, showed that geriatric syndromes
(disability, multimorbidity, frailty, malnutrition) were
hardly taken into account in studies testing the efficacy
of antidepressants in later life [21]. Therefore, it remains
difficult to what extent these characteristics may explain
worse treatment results with increasing age as well as to
what extent older patients included in treatment trials
are representative for the patients we see in daily care.
Considering that even in younger age groups, only 17–
25% of the regular care patients would qualify for
participation in antidepressant efficacy trials [22], this
figure is probably much worse in later life.
Clinical cohort studies may fill the gap left by random-
ized controlled trials as they represent patients and
outcomes in regular care rather than the optimized
situation of an RCT. Cohort studies in psychiatry are,
however, limited by convenience sampling, a focus on
one type of disorder, restricted monitoring of treatment
provided, and long intervals between assessments (e.g.
[23, 24]). Moreover, in later life, cohort studies of anxiety
disorders and somatoform disorders are lacking.
Routine outcome monitoring (ROM) which has been
implemented in different services in the Netherlands
and internationally offers another possibility to assess
the effectiveness of protocolled interventions in daily
care that were implemented on the basis of evidence
from RCTs in selected populations [25]. Unfortunately,
an optimal scientific study design may conflict with the
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practical use of ROM systems to facilitate routine clin-
ical care. Whereas assessment of only one outcome
measure may be sufficient for ROM application in
routine clinical care [26], the answer to a broader range
of (fundamental) research questions may be hindered by
inadequate confounder control, selective participation
and dropout, and low quality of diagnostic assessment
[27, 28]. Incorporating all the necessary instruments in
day-to-day ROM systems will increase patient burden
and translates to higher number of missing data and
early dropouts, again threatening the external validity of
extended ROM data.
To overcome the limitations of traditional clinical co-
hort studies and ROM, we have designed the Routine
Outcome Monitoring for Geriatric Psychiatry & Science
(ROM-GPS) project. ROM-GPS is a two-stage project.
The first stage is simply an improvement of routine clin-
ical care by extending the diagnostic intake at specialised
mental health outpatient clinics for older persons with a
standardised diagnostic assessment performed by trained
personnel independent of the health care professional
who is responsible for intake and treatment. In case
patients have an affective disorder, they are asked for
informed consent to participate in the second stage of
ROM-GPS. The second stage is a cohort study with an
extended baseline assessment, follow-up assessments
and treatment monitoring.
Objectives
The primary aim of the ROM-GPS project is to study
the one-year outcome (remission) of late-life depressive-,
anxiety- and somatic symptom disorders jointly. ROM-
GPS specifically aims to estimate the impact of comorbid-
ity between affective disorders, the treatment components
delivered, and age-related characteristics on treatment
effectiveness. Such knowledge will guide the development
of more effective and age-specific treatment strategies.
Methods/design
Study design
ROM-GPS offers an infrastructure for collecting high-
quality research data on treatment effects for late-life
affective disorders in specialised mental health care, with
detailed assessment of the delivered treatment (see
below). This infrastructure is established in the Northern
and central regions of the Netherlands.
ROM-GPS is in fact a clinical cohort study, enriched
with principles of ROM, designed as a two-stage project.
Designated outpatient mental health clinics for geriatric
psychiatry have standardized and protocolized their
intake procedure for new referrals by adding a diagnostic
assessment by a research nurse within two weeks after
the initial contact with a mental health professional. The
research nurse will administer the semi-structured
psychiatric interview, based on the Mini International
Neuropsychiatric Interview Plus (MINI-Plus, see below),
for a full diagnostic assessment [29, 30], as well as the
Montreal Cognitive Assessment (MoCA) [31], a brief
cognitive screening tool. To guarantee high data quality,
research nurses are well-trained at the Rob Giel Re-
search center. Prior to formal data collection, research
nurses have to attend a one-day training class as well as
to observe two intakes of an experienced ROM-GPS
research nurse. Moreover, the first two assessments will
be supervised by a senior ROM-GPS research nurse to
check procedures and data quality. During the study, re-
search nurses participate in three obligatory training
days each year, and receive regular supervision by a geri-
atric psychiatrist. In addition to the adapted MINI-Plus
interview, four self-report questionnaires are adminis-
tered to assess severity of depressive symptoms (30-item
Inventory of Depressive Symptoms, IDS) [32], anxiety
symptoms (Geriatric Anxiety Inventory, GAI) [33],
hypochondria (Whitley Index, WI) [34, 35], and alcohol
usage (Alcohol Usage Identification Test, AUDIT) [36].
These questionnaires have been chosen for their applic-
ability and good psychometric properties in an older
population.
Patients who meet the in- and exclusion criteria, will
be informed orally and in writing about the research part
of the project. After (at least) one week, patients will be
asked whether they are interested to participate in the
second stage of the project. For this stage informed
consent is to be signed, where after a detailed assess-
ment of patients is performed, including the administra-
tion of some extra observer-rated and self-report
questionnaires, a brief physical examination, and a
cognitive test battery (for overview see Table 1, for
additional information see below). These patients will be
monitored every four months by postal questionnaires
(see also Table 1), which focus on re-assessment of
psychiatric symptom severity. At one-year follow-up or
end of treatment if treatment is concluded earlier, all
baseline characteristics amenable to change will be reas-
sessed during a site-visit. Two years after the detailed
assessment at baseline, a postal questionnaire, similar to
the four-month assessments will be conducted as a last
follow-up assessment.
ROM-GPS is designed as an ongoing project, allowing
to replace or add specific measurements once a year.
ROM-GPS has started on 1 January 2015 at the depart-
ment of psychiatry of the University Medical Center
Groningen and GGZ Noord-Holland Noord.
Participants and setting
The domain population for the ROM-GPS project are all
patients aged 60 years and older who are referred to one
of the participating outpatient clinics for specialised
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geriatric mental health care, i.e. the outpatient clinic for
geriatric psychiatry of the University Medical Center
Groningen and affiliated mental health centers (GGZ
Noord-Holland Noord per 01-01-2015, GGNet per 01-
09-2016, GGZ Centraal per 01-01-2017, GGZ Drenthe
per 01-04-2017, Mediant per 01-02-2018, and Pro
Persona per 01-03-2019).
Inclusion criteria for the research part of the project
(stage II) are 1) an age of 60 years or older, 2) the
presence of an affective disorder confirmed by the Mini
International Neuropsychiatric Interview-Plus (MINI-
Plus), and 3) given informed consent.
As the MINI-Plus has been developed for the assess-
ment of DSM-IV disorders, we have made some minor
adaptations in the sections for mood and anxiety
disorders to meet DSM-5 criteria for these disorders.
Unipolar depressive disorders that will be assessed are:
unipolar major depressive disorder (single /recurrent
episode), persistent depressive disorder (dysthymia), and
depressive disorder due to another medical condition.
Anxiety disorders that will be assessed are panic dis-
order, agoraphobia, social anxiety disorder and general-
ized anxiety disorder. Bipolar disorders will be assessed
(but will lead to exclusion of the patient, see below).
Obsessive-compulsive disorder and posttraumatic stress
disorder will also be assessed (but only allowed as co-
morbidity for inclusion in the study). As the DSM-IV
section of somatoform disorders (DSM-IV) has been
replaced by the DSM-5 section of somatic symptom
disorders (DSM-5), we made major adaptations for this
part of MINI-Plus especially new questions for assessing
a somatic symptom disorder. Therefore, we will assess
only the presence of a somatic symptom disorder,
including the specifier with predominant pain, as well as
illness anxiety disorder (similar to hypochondria in
DSM-IV).
Finally, subthreshold depression and panic disorders
will be considered (as comorbid disorders). Subthreshold
depression will be defined according to the DSM-IV-TR
research criteria for minor depression. Subthreshold
panic disorder will be established by skipping the rules
for panic disorders with respect to absence of a
situational trigger of the panic attacks, peaking of the at-
tacks within 10min, and minimum number of somatic
or cognitive symptoms required (1 instead of 4), enab-
ling us to also report on atypical panic attacks and panic
attacks with limited symptoms.
Exclusion criteria for the research part of the project
(stage II) are 1) an established diagnosis of a neurode-
generative disorder or less than 18 points on the
Montreal Cognitive Assessment (MoCA) test, 2) a (his-
tory of a) bipolar or psychotic disorder, 3) a severe
substance-use disorder in need of specialised treatment,
4) physically or mentally too handicapped to administer
self-report questionnaires or perform cognitive testing,
or 5) insufficient mastery of the Dutch language. The
MoCA is a short screening instrument for cognitive
function [31], which covers the domains attention and
concentration, memory, orientation, language, visuocon-
structional skills, conceptual thinking, calculations and
executive functions. Meta-analysis has shown that a cut-
off of 23 out of 30 points differentiates best between
healthy persons and those with a neurocognitive dis-
order [37]. As affective disorders, primarily depressive
and generalized anxiety disorder, may interfere with
cognitive functioning, we only excluded patients scoring
less than 18 points (whose score is classified as indicat-
ing ‘moderate [score 10-17] or severe [less than 10] cog-
nitive impairment’ versus ‘mild cognitive impairment
[18–26] or normal [more than 26]; although validation
of these severity ranges in a psychiatric sample has not
been established yet; see http://www.mocatest.org/faq/).
At the start of the project, we originally included the
Mini Mental State Examination (MMSE) [38], but
replaced the MMSE by the MoCA per 01-01-2016, as
the MoCA explicitly covers executive functions in con-
trast to the MMSE, which is associated with late-onset
depressive disorder and late-life anxiety disorder and
therefore particularly relevant to reassess at one year
follow-up.
Outcome variables
 The primary outcome variable is remission of the
index affective disorder (yes/no), assessed with the
MINI-Plus at one-year follow-up or end of treat-
ment if specialized mental health care is concluded
earlier.
 Secondary outcome measures include the course of
symptom severity of the index disorder which will
be measured every four months by well-validated
self-report questionnaires (see Table 1).
Depressive symptom severity will be monitored with
the 30-item self-rating Inventory of Depressive
Symptomatology (IDS), which has adequate psycho-
metric properties [32]. The sum score ranges from 0
to 60; the severity of depression can be classified as
none (score range 0 through 12), mild (13 though
24), moderate (25 through 37), severe (38 through
47) and very severe (48 or higher). Severity of som-
atic symptom disorders is assessed with the Whitley
Index (WI) [39]. The WI has 14 statements (yes/no)
addressing the severity of hypochondriacal cogni-
tions and somatization symptoms [39]. The course
of anxiety disorders will be monitored with the 20-
item Geriatric Anxiety Inventory, which has specific-
ally been developed for measuring anxiety in older
persons [33]. In addition, disorder specific
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instruments will be applied to monitor the severity
of the individual anxiety disorders. The Mobility
Inventory – Avoidance scale (MI-A) [40] will be
administered to monitor agoraphobic severity in pa-
tients with panic disorder or agoraphobia, the Penn
State Worry Questionnaire (PSWQ) [41] to monitor
the course of generalized anxiety disorder, and the
Leibowitz Social Anxiety Scale (LSAS) [42] for the
course of social anxiety.
 Functional limitations will be assessed at baseline
and one year follow-up with the WHO-Disability
scale (WHO-DAS II) [43].
 As all secondary outcome variables are self-report
measures, these will be re-administered at two-year
follow-up by a postal questionnaire.
Primary determinants
As determinants of treatment effectiveness, we will
examine the different treatment modalities and their in-
tensity offered to patients as well as age-related physical
and cognitive patient characteristics.
 Psychiatric treatment is assessed at baseline and
one-year follow-up with the aid of a self-developed
checklist of treatment modalities and intensity. We
will administer the number of contacts per discipline
(physician, psychiatrist, psychologist, etc.), setting
(outpatient clinic, home visits, day care, inpatient
care), and content of treatment provided. The con-
tent will be classified as drug treatment, psycho-
therapeutic treatment or structured/supportive
treatment. Structured/supportive treatment is de-
fined as all non-pharmacological treatment delivered
by health care professionals with a degree below a
Master of Science/Arts level (the minimum level for
psychologists and physicians). In case of drug treat-
ment, we will collect the generic name, Anatomical
Therapeutic Chemical (ATC) code, dose, and
whether blood levels were assessed. In case of psy-
chotherapeutic treatment, the psychotherapy will be
classified as cognitive behavioral therapy, interper-
sonal psychotherapy, problem solving treatment,
mindfulness based cognitive therapy, or other. At
one-year follow-up, the research nurse will collect
these data from the (electronic) medical records for
each of the 4-month follow-up periods. Since reim-
bursement of mental health care in the Netherlands
is based on the number of minutes spent by each
mental health professional, registration of these data
is considered accurate.
 Multimorbidity will be measured by inquiring about
the most common chronic somatic diseases, using a
validated self-report questionnaire previously used in
the Netherlands Study of Depression in Older
persons (NESDO) and validated in the Longitudinal
Aging Study Amsterdam (LASA) [23, 44]. Prescribed
drug use at baseline and one-year follow-up will be
registered. For each drug taken in the past month,
we will assess the generic name, ATC-code, fre-
quency of use, daily dosage, and in case of psycho-
tropic drugs, also duration of use. This enables to
examine the number of prescribed drugs (or specific
polypharmacy definitions) as determinant of treat-
ment outcome. For more specific research questions,
the number of prescribed drugs, changes over one
year or specific (somatic) drugs, can be included as
covariate.
 Frailty will be assessed according to both a
biomedical and a broad phenotype at baseline and
one-year follow-up. The physical frailty phenotype
will be assessed according to Fried [45]. This Fried
Frailty Index consists of five criteria and physical
frailty is considered present when three or more
criteria are met, i.e. 1) unintentional weight loss of
more than 4.5 kg in the past year, 2) low level of
physical activities assessed with the International
Physical Activity Questionnaire (IPAQ, see below),
3) exhaustion, based on a positive answer on one
out of two items of the Center for Epidemiological
Studies Depression scale, 4) low grip strength ac-
cording to body mass index and sex, assessed with a
dynamometer and 5) low gait speed according to
body length and sex.
Secondly, the Tilburg Frailty Indicator (TFI) will be
administered to assess the broad frailty phenotype
[46, 47]. The TFI is a self-report questionnaire, based
on a Delphi study among a panel of international
frailty experts and validated in cross-sectional
studies.
In addition, a physical examination will be
performed to assess weight (kg), length (cm), waist
circumference (cm), blood pressure (mmHg), the
metabolic syndrome according to the National
Cholesterol Education Program (NCEP)-Adult
Treatment Panel III guidelines [48] and the
accumulation of advanced glycation endproducts
(AGE) in the skin reflecting lifetime metabolic
dysregulation [49, 50].
 In addition to the MoCA, cognitive functioning will
be more extensively tested during baseline and
one-year follow-up. Firstly, we will apply the com-
puterized Cogstate test battery (http://www.cogstate.
com), including the Detection Test measuring
psychomotor function, the Identification Test
measuring attention, the One Card Learning Test
measuring visual learning, and the One Back Test
measuring working memory. In addition to these
computerized tasks, we also administer some
Oude Voshaar et al. BMC Psychiatry          (2019) 19:182 Page 7 of 12
traditional paper and pencil tests [51]. These include
an abbreviated version of the Stroop Colour-word
test [52] for processing speed and executive func-
tioning, the subtest Digit Span from the Wechsler
Adult Intelligence Scale [53] for working memory
and a modified version (10-words test) of the
Auditory Verbal Learning Test [54, 55] for verbal
memory.
Secondary determinants and potential confounders
As potentially interesting determinants and confounding
variables, we will assess age, sex, level of education,
partner status, the BIG-five personality traits, early and
recent life-events, extent of social network, loneliness,
lifestyle characteristics (including alcohol usage, smok-
ing, sleep, physical activity) and self-management
abilities.
The Big Five personality traits –openness to experi-
ence, conscientiousness, extraversion, agreeableness and
neuroticism- will be assessed using the NEO Five Factor
Inventory (NEO-FFI) [56]. Negative life events in
childhood and adolescence concerning emotional,
physical and sexual abuse were will measured with the
NEMESIS questionnaire [57]. The list of threatening ex-
periences [58] will be used to inquire about 12 categories
of negative life events in the past year, such as the death
of a family member, divorce or financial problems.
Extent of social network and loneliness will be
assessed with the Social Network Index [59] and the 11
item Loneliness scale [60], respectively.
Assessment of lifestyle characteristics will include
smoking, alcohol use, sleep, and physical activities.
Smoking behaviour is assessed with standard questions,
and the use of alcohol is assessed using the Alcohol Use
Disorders Identification Test (AUDIT) [36]. Sleep will be
assessed with the Insomnia Rating Scale (IRS) [61].
Finally, the International Physical Activities Question-
naire (IPAQ) [62] will be used to measure energy ex-
penditure based on sports and daily activities. Abilities
for self-management of wellbeing will be measured with
the Self-Management Abilities Scale (SMAS-30) [63].
Table 1 presents an overview of all instruments
applied, including the moment of administration, i.e. at
intake (stage one), at baseline (start of stage two), every
four months during the first year of treatment, at one-
year follow-up or end of treatment when treatment is
concluded within one year, and finally at two-year
follow-up.
Statistical analyses
The effect of a determinant on the primary outcome, re-
mission of the index disorder at one year follow-up, will
be examined by logistic regression analysis. Depending
on the specific objective of specific studies that will be
embedded in ROM-GPS, comorbidity between affective
disorders can be addressed in different ways. Firstly, co-
morbidity can be included as a covariate to adjust for
the presence of comorbidity. Secondly, by having a
sample of well-phenotype patients, a sensitivity analysis
on patients with a ‘pure’ affective disorder can be per-
formed. Finally, if theoretically grounded, our research
design also allows to examine the interaction between spe-
cific comorbid affective disorders and other determinants.
The effect on the secondary outcome, course of symp-
tom severity, will be examined by random coefficient
analysis, a specific type of linear mixed models, which
takes into account that the repeated assessments of
symptom severity are nested within subjects [64]. In
random coefficient analysis, the development in the
outcome variable is estimated by a straight line and the
effect of the determinant on this linear development is
tested by the interaction of the determinant with the
time of assessment of the outcome variable. All analyses
will be controlled for potential confounders.
Power calculation
Applying logistic regression analysis for the primary out-
come variable remission at one-year follow-up, requires
a sample size of 231 patients to demonstrate the effect
of a continuous determinant with an odd ratio of 1.4 per
standard deviation (which is equivalent to a small effect
size d of 0.2) with a power of 80% and a significance
level of 5%, assuming a one-year remission rate of 50%
at the mean of the determinant [65, 66]. With a sample
size of 231 patients, ordinary linear regression can
demonstrate the effect of a continuous determinant
which explains 4% of variance in change in a continuous
outcome variable (e.g. change between baseline and
follow-up on the secondary outcome measures) with a
power of 87%. This power further increases when mul-
tiple repeated assessments of the outcome variable (e.g.
the four-monthly assessments of symptom severity) are
examined as outcome using random coefficient analysis.
To achieve a sample of 231 patients with a complete
baseline and follow-up assessment, we estimate that 289
patients have to give informed consent assuming a 20%
dropout rate at one-year follow-up [67]. Moreover,
assuming an overlap between depressive, anxiety and
somatic symptom disorders of at least 50%, analyses per
diagnostic main group can be performed when approxi-
mately 600 patients have completed the study protocol.
Ethical issues
The first stage is implemented at the participating
outpatient clinics as part of routine clinical care. All pa-
tients of the participating mental health organisations
are informed in writing at intake that data collected as
part of routine clinical care may anonymously be used
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for research. When the first stage shows that patients
meet the in- and exclusion criteria of the study, they are
informed orally and in writing about the second stage of
the project and are asked whether they may be
contacted after one week, to hear whether they want to
participate in the study. If so, an appointment is made
for the baseline assessment, which starts with and only
continues when written informed consent for the study
is provided.
Before the start, all relevant documents have been sub-
mitted to the ethical review board of the University
Medical Center Groningen (METc 2014/106), which con-
cluded that the project is fully in line with the Dutch law
(NL47717.042.14). ROM-GPS has been registered at the
Dutch Trial Register (NTR6874) (www.trialregister.nl).
Data-management
Data collection is supported by an online data entry and
management system, i.e. Routine Outcome Quality
Assessment (ROQUA, see https://www.roqua.nl), devel-
oped by the University Medical Center Groningen and
the Rob Giel Research center. In case of a self-report
questionnaire, patients can choose whether they want to
fill in the questionnaire on the computer or prefer a
paper and pencil version (which is entered in the online
system afterwards by the research nurse).
Discussion
Relevance of expected findings
ROM-GPS will produce important new information
about the actual effectiveness of interventions for late-
life affective disorders in day-to-day mental health care.
The population aged 60 or over is growing faster than
all younger age groups. Globally, the number of persons
aged 60 years will more than double by 2050 to 2.1
billion [68] of which at least every tenth will be con-
fronted with common mental disorders [1–5] and may
seek treatment. Knowledge regarding real life outcomes
of those treatment is highly relevant in light of the
disease burden of this group of disorders. Current treat-
ment strategies, even under optimal circumstances, only
achieve modest effects. In depth knowledge of ageing-
related determinants as well as their relative contribu-
tion on treatment outcome and negative health
consequences, may facilitate adaptation of current
treatment strategies to address the most important
determinants or their consequence more targeted and
thus guide the development of new interventions for
specific subgroups [69, 70]. Promising examples include
psychotherapy adapted to (mild) cognitive deficits [71],
optimizing cardiovascular treatment [72], or addressing
biomedical frailty [69, 73]. In case of biomedical frailty,
for example, antidepressants should be avoided to
prevent polypharmacy and falls, while psychological
treatment should also address coping with an ageing
body (e.g. physiological exhaustion) and should prefera-
bly augmented with components of geriatric rehabilita-
tion like protein rich diets and physical exercise. Results
may thus directly guide clinical care and may lead to im-
provement of guidelines by early detection of treatment
resistant groups.
ROM-GPS is worldwide the first study in which late-
life depressive, anxiety and somatic symptom disorders
are studied jointly using a unique hybrid design that
combines the possibilities of ROM with more rigorous
standardized assessments and follow-up measures.
ROM-GPS adds to current practice as the use of (semi-)
structured diagnostic psychiatric interviews is not
standard practice in the Netherlands. Moreover, only a
minority of patients receive ROM [27], despite recom-
mendations in care standards and guidelines [www.
ggzstandaarden.nl]. Furthermore, in case ROM is
systematically implemented, only a few outcome instru-
ments are used (comparably to our 4 and 8month
follow-up) [74], but no extensive baseline and outcome
assessment as implemented in ROM-GPS for those
patients giving informed consent. Therefore, our data
collection enables to examine the impact of comorbidity
on treatment outcome and disease burden. Hopefully,
data collection may also assist the development of a bet-
ter classification for affective disorders in later life.
DSM- and ICD-classification systems are often criticized
for the (potential) lack of age-neutrality of the criteria
for mental disorders [75, 76]. Empirical studies support-
ing a more optimal age-specific classification, however,
are hardly available. Since ROM-GPS includes three
groups of extensively phenotyped affective disorders, ap-
plication of data-driven techniques may be employed to
support the development of a classification system that
fits more accurately the affective symptoms experienced
by older persons.
Methodological considerations
By collecting these data with the aid of well-trained
nurse practitioners or psychologists, the quality of the
psychiatric diagnosis of both participants and non-
responders is high. Since the first diagnostic assessment
is done within the framework of care, research will feel
like less of a burden to patients. Moreover, clinicians
and patients will benefit as diagnostic data will become
directly available for the mental health team. During
stage one, data of all patients referred to the participat-
ing outpatient clinics are gathered. These data enable us
to examine the representativeness of our study sample.
In case of selection bias due to differential refusal rates
between specific subgroups, findings may be adjusted
using ‘propensity score matching’ [77]. To do so reliably,
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still sufficient numbers of participants are necessary of
such subgroups.
The main limitation is probably the burden of the
baseline assessment for patients giving informed consent
(stage 2). This assessment takes approximately 3–4 h,
which may affect patients’ willingness to participate.
Nonetheless, our experience with the NESDO study
reveals that many patients actually appreciate the thor-
ough investigations done as part of clinical research [23].
Moreover, the assessment can be spread over 2 visits if
necessary.
Secondly, we aim to conduct the extensive baseline as-
sessment as soon as possible, but for pragmatic reasons,
we consider a period up to 14 days as acceptable. Since
symptoms my readily change after the first contact with
specialised mental health care, this delay might con-
found results. Nonetheless, as the time between intake
and baseline assessment is known, we can adjust for this
time period and where relevant, also can perform sensi-
tivity analyses on the subgroup that was assessed within
one week.
Final conclusion
The ROM-GPS study will show how effective the treat-
ments are which are routinely provided in outpatient
geriatric psychiatry, and to what extent this effectiveness
is compromised by the typical characteristics of an eld-
erly population. This will indicate whether standard
treatments need to be adjusted and supplemented.
Furthermore, it will provide a good infrastructure for
patient selection for additional studies in our Regional
Geriatric Psychiatry Network.
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